Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Liquidity Ratios (Summary)

Pfizer Inc., liquidity ratios (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Current ratio
Quick ratio
Cash ratio

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The liquidity profile of the organization exhibits significant volatility over the analyzed period, characterized by a substantial peak in late 2023 followed by a sharp correction and subsequent stabilization at lower levels through early 2026.

Current Ratio
The current ratio fluctuated between a minimum of 0.86 and a peak of 2.38. A steady upward trend was observed from April 2022 to October 2023, after which the ratio experienced a precipitous decline to 0.91 by December 31, 2023. From 2024 through March 2026, the ratio stabilized, generally oscillating between 0.86 and 1.26, ending the period at 1.25.
Quick Ratio
A parallel trajectory is evident in the quick ratio, which reached its maximum of 1.78 in October 2023 before falling sharply to 0.50 by the end of the same year. Throughout 2024 and 2025, the ratio remained consistently below 1.0, indicating that highly liquid assets, excluding inventory, were insufficient to cover current liabilities. A gradual recovery is noted toward the end of the period, with the ratio reaching 0.75 by March 2026.
Cash Ratio
The cash ratio demonstrated the most pronounced volatility, peaking at 1.42 in October 2023 and plummeting to 0.27 by December 31, 2023. For the remainder of the observed period, the ratio fluctuated within a restricted range between 0.16 and 0.48, suggesting a strategic shift in cash management or a significant reallocation of liquid capital.

The simultaneous peaking and subsequent decline of all three liquidity metrics in late 2023 point to a significant liquidity event or a major shift in the balance sheet structure during that quarter. While the current ratio has returned to a level above 1.0, the sustained lower values of the quick and cash ratios suggest an increased reliance on inventory or other less liquid current assets to meet short-term obligations compared to the levels maintained in 2022.


Current Ratio

Pfizer Inc., current ratio calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The liquidity position of the organization exhibited substantial volatility from April 2022 through early 2024, characterized by significant fluctuations in both current assets and current liabilities. Following a period of sharp contraction, the liquidity profile transitioned into a phase of relative stabilization from mid-2024 through March 2026.

Liquidity Peaks and Expansion
A period of expanding liquidity is observed between April 2022 and October 2023. The current ratio climbed from 1.39 to a peak of 2.38 by October 1, 2023. This trend was primarily driven by a substantial increase in current assets, which reached a high of 74,012 million US dollars during the same period, while current liabilities remained relatively contained.
Liquidity Contraction and Compression
A sharp decline in the current ratio occurred between October 2023 and December 2023, where the ratio dropped from 2.38 to 0.91. This compression was the result of a simultaneous decrease in current assets to 43,333 million US dollars and a surge in current liabilities to 47,794 million US dollars. This represents the lowest liquidity point in the analyzed period, indicating a temporary state where short-term obligations exceeded available liquid assets.
Stabilization and Recovery Phase
From March 2024 through March 2026, the current ratio stabilized, generally fluctuating between 0.86 and 1.28. While a brief dip to 0.86 was noted in June 2024, the ratio recovered and maintained a consistent range above 1.10 for much of 2025 and early 2026. This suggests a more balanced management of short-term working capital, with current assets typically maintaining a modest surplus over current liabilities.

Quick Ratio

Pfizer Inc., quick ratio calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Short-term investments
Trade accounts receivable, net of allowance for doubtful accounts
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The liquidity profile of the entity exhibits significant volatility over the analyzed period, characterized by a period of expansion followed by a sharp contraction and a subsequent phase of stabilization. The ability to cover short-term obligations without relying on inventory sales has fluctuated considerably, moving from a position of strength to one of relative constraint before settling into a moderate range.

Quick Asset Volatility
Total quick assets experienced a notable increase in the early stages, peaking at US$ 55.27 billion in October 2023. This was followed by a precipitous decline to a low of US$ 18.49 billion by June 2024. In the latter half of the period, quick assets stabilized, fluctuating between US$ 25.33 billion and US$ 31.94 billion.
Current Liabilities Dynamics
Short-term obligations showed a non-linear trend, with peaks observed in July 2022 (US$ 47.41 billion) and December 2023 (US$ 47.79 billion). A gradual downward trend in liabilities is evident from December 2023 onward, concluding at US$ 34.35 billion by March 2026, which indicates a reduction in short-term debt or accrued expenses.
Quick Ratio Performance
The quick ratio demonstrated a strong upward trajectory from April 2022 (0.95) to a peak of 1.78 in October 2023, suggesting a period of high liquidity. A severe contraction occurred between December 2023 and June 2024, during which the ratio dropped to 0.50 and then to a minimum of 0.42. Since September 2024, the ratio has recovered and maintained a range between 0.67 and 0.80, ending the period at 0.75.

The convergence of declining quick assets and peaking current liabilities in late 2023 and early 2024 created a significant liquidity squeeze. However, the subsequent reduction in current liabilities coupled with a modest recovery in quick assets has mitigated the risk, though the ratio remains below the 1.0 threshold observed during the 2022-2023 peak.


Cash Ratio

Pfizer Inc., cash ratio calculation (quarterly data)

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Short-term investments
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q1 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The cash ratio exhibits significant volatility over the analyzed period, characterized by a dramatic peak in mid-2023 followed by a sharp contraction and subsequent stabilization. The liquidity position shifted from a highly conservative stance to a leaner operational structure.

Liquidity Peak and Contraction
The cash ratio reached its apex on October 1, 2023, at 1.42, indicating a period where cash assets significantly exceeded current liabilities. This peak was preceded by a steady climb starting in early 2022. However, a precipitous decline occurred by December 31, 2023, where the ratio fell to 0.27, eventually reaching a period low of 0.16 by June 30, 2024.
Cash Asset Dynamics
Total cash assets peaked in July 2023 at 44,785 million US$, but underwent a substantial reduction, hitting a low of 7,100 million US$ by June 30, 2024. A recovery was observed toward the end of 2024, with assets rising to 20,477 million US$ by September 29, 2024, before consolidating between 13,075 million US$ and 17,317 million US$ through March 2026.
Current Liability Influence
Current liabilities fluctuated throughout the period, peaking at 47,794 million US$ in December 2023. The simultaneous increase in liabilities and the sharp decrease in cash assets during the fourth quarter of 2023 acted as the primary catalyst for the rapid compression of the cash ratio.

From December 2024 through March 2026, the cash ratio demonstrated a period of relative stability, fluctuating within a narrow band between 0.35 and 0.48. This trend suggests the establishment of a more consistent liquidity baseline following the high volatility observed in the 2023-2024 window.